Related references
Note: Only part of the references are listed.Treatment of Mycobacterium abscessus Pulmonary Disease
David E. Griffith et al.
CHEST (2022)
Minimal Inhibitory Concentration of Clofazimine Among Clinical Isolates of Nontuberculous Mycobacteria and Its Impact on Treatment Outcome
Nakwon Kwak et al.
CHEST (2021)
In Vitro Susceptibility Testing of Omadacycline against Nontuberculous Mycobacteria
Barbara A. Brown-Elliott et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
In vitro susceptibility of Mycobacterium abscessus complex and feasibility of standardizing treatment regimens
Ka Lip Chew et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
In vitro pharmacodynamics of omadacycline against Escherichia coli and Acinetobacter baumannii
A. R. Noel et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Preliminary, Real-world, Multicenter Experience With Omadacycline for Mycobacterium abscessus Infections
Taylor Morrisette et al.
OPEN FORUM INFECTIOUS DISEASES (2021)
β-Lactam Combinations That Exhibit Synergy against Mycobacteroides abscessus Clinical Isolates
Elizabeth Story-Roller et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Differential In Vitro Activities of Individual Drugs and Bedaquiline-Rifabutin Combinations against Actively Multiplying and Nutrient-Starved Mycobacterium abscessus
Jin Lee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
In Vivo Pharmacodynamic Evaluation of Omadacycline against Staphylococcus aureus in the Neutropenic Mouse Pneumonia Model
Alexander J. Lepak et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Omadacycline in the Treatment of Mycobacterium abscessus Infection
Miguel G. Madariaga
CLINICAL INFECTIOUS DISEASES (2020)
Assessment of Clofazimine and TB47 Combination Activity against Mycobacterium abscessus Using a Bioluminescent Approach
Yang Liu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent
George G. Zhanel et al.
DRUGS (2020)
Repurposing drugs for treatment of Mycobacterium abscessus: a view to a kill
Tawanda Gumbo et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Intraperitoneal Route of Drug Administration: Should it Be Used in Experimental Animal Studies?
Abdullah Al Shoyaib et al.
PHARMACEUTICAL RESEARCH (2020)
A mouse model of pulmonary Mycobacteroides abscessus infection
Emily C. Maggioncalda et al.
SCIENTIFIC REPORTS (2020)
Efficacy of Bedaquiline, Alone or in Combination with Imipenem, against Mycobacterium abscessus in C3HeB/FeJ Mice
Vincent Le Moigne et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline: Executive Summary
Charles L. Daley et al.
CLINICAL INFECTIOUS DISEASES (2020)
Omadacycline for the Treatment of Mycobacterium abscessus Disease: A Case Series
Jeffrey C. Pearson et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
In Vitro Activities of Omadacycline against Rapidly Growing Mycobacteria
Carolyn Shoen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Omadacycline for Acute Bacterial Skin and Skin-Structure Infections
William O'Riordan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Omadacycline for Community-Acquired Bacterial Pneumonia
Roman Stets et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
In Vivo Pharmacodynamics of Omadacycline against Staphylococcus aureus in the Neutropenic Murine Thigh Infection Model
Alexander J. Lepak et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessus
Amit Kaushik et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus
Hannelore I. Bax et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial
William O'Riordan et al.
LANCET INFECTIOUS DISEASES (2019)
A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria
Mike Marvin Ruth et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Mycobacterium abscessus: Environmental Bacterium Turned Clinical Nightmare
Rose C. Lopeman et al.
MICROORGANISMS (2019)
Activities of Dual Combinations of Antibiotics Against Multidrug-Resistant Nontuberculous Mycobacteria Recovered from Patients with Cystic Fibrosis
Matthew Schwartz et al.
MICROBIAL DRUG RESISTANCE (2018)
Phylogenomics and Comparative Genomic Studies Robustly Support Division of the Genus Mycobacterium into an Emended Genus Mycobacterium and Four Novel Genera
Radhey S. Gupta et al.
FRONTIERS IN MICROBIOLOGY (2018)
British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)
Charles S. Haworth et al.
THORAX (2017)
Bedaquiline Inhibits the ATP Synthase in Mycobacterium abscessus and Is Effective in Infected Zebrafish
Christian Dupont et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects
Mark H. Gotfried et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Microbiological and Clinical Outcomes of Treating Non Mycobacterium Avium Complex Nontuberculous Mycobacterial Pulmonary Disease: A Systematic Review and Meta-Analysis
Roland Diel et al.
CHEST (2017)
Clofazimine-Containing Regimen for the Treatment of Mycobacterium abscessus Lung Disease
Bumhee Yang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model
Alexander J. Lepak et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Adult Patients With Bronchiectasis A First Look at the US Bronchiectasis Research Registry
Timothy R. Aksamit et al.
CHEST (2017)
US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis
R. Andres Floto et al.
THORAX (2016)
US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis
Patrick A. Flume
JOURNAL OF CYSTIC FIBROSIS (2016)
The antimicrobial susceptibility of non-tuberculous mycobacteria
S. Cowman et al.
JOURNAL OF INFECTION (2016)
Characterization of Mouse Models of Mycobacterium avium Complex Infection and Evaluation of Drug Combinations
Claire Andrejak et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Susceptibility of Mycobacterium abscessus to Antimycobacterial Drugs in Preclinical Models
Andres Obregon-Henao et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Epidemiology of Human Pulmonary Infection with Nontuberculous Mycobacteria A Review
D. Rebecca Prevots et al.
CLINICS IN CHEST MEDICINE (2015)
In Vitro and In Vivo Antibacterial Activities of Omadacycline, a Novel Aminomethylcycline
A. B. Macone et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Mechanism of Action of the Novel Aminomethylcycline Antibiotic Omadacycline
Michael P. Draper et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections
Richard J. Wallace et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
In Vivo Evaluation of Antibiotic Activity Against Mycobacterium abscessus
Isabelle Lerat et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
A Randomized, Evaluator-Blind, Phase 2 Study Comparing the Safety and Efficacy of Omadacycline to Those of Linezolid for Treatment of Complicated Skin and Skin Structure Infections
Gary J. Noel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
In Vitro Synergy between Clofazimine and Amikacin in Treatment of Nontuberculous Mycobacterial Disease
Jakko van Ingen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria
Jakko van Ingen et al.
DRUG RESISTANCE UPDATES (2012)
Mycobacterium abscessus: a new antibiotic nightmare
Rachid Nessar et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Comparative Studies Evaluating Mouse Models Used for Efficacy Testing of Experimental Drugs against Mycobacterium tuberculosis
Mary A. De Groote et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Clinical and Microbiologic Outcomes in Patients Receiving Treatment for Mycobacterium abscessus Pulmonary Disease
Julie Jarand et al.
CLINICAL INFECTIOUS DISEASES (2011)
Activities of Rifampin, Rifapentine and Clarithromycin Alone and in Combination against Mycobacterium ulcerans Disease in Mice
Deepak Almeida et al.
PLOS NEGLECTED TROPICAL DISEASES (2011)
Antibiotic Treatment of Mycobacterium abscessus Lung Disease A Retrospective Analysis of 65 Patients
Kyeongman Jeon et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2009)
Spontaneous reversion of Mycobacterium abscessus from a smooth to a rough morphotype is associated with reduced expression of glycopeptidolipid and reacquisition of an invasive phenotype
Susan T. Howard et al.
MICROBIOLOGY-SGM (2006)
Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria
BA Brown-Elliott et al.
CLINICAL MICROBIOLOGY REVIEWS (2002)
Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis
T Yoshimatsu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Share Paper
